Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Eisai Inc.

Hiroshi Shirota

Kenichi Chiba

Isao Yamatsu

Masaki Goto

Hideki Sakurai

Takeshi Suzuki

Kenzo Muramoto

Ryoichi Hashida

Kouichi Katayama

Toshihiko Kaneko

Jean-Christophe P Harmange

Shigeru Souda

Yoshimasa Machida

Mark Spyvee

Shigeki Hibi

Seiichiro Nomoto

Katsuya Tagami

Yasushi Okamoto

Makoto Okita

Satoshi Yamamoto

Naoki Yoneda

Tomohiro Matsushima

Makoto Kotake

Yoshiyuki Kawakami

Hong Du

Hideki Ono

Yoshiharu Mizui

Fabian Gusovsky

Masayuki Tanaka

Isao Tanaka

Hideto Ohhara

Yoshikazu Kuboi

Masanori Fujita

Yoshihito Eguchi

John (Yuan) Wang

Akifumi Kimura

Takatoshi Kawai

Yong-Chun Shen

Megumi Kawada

Shinya Abe

Hiroyuki Yoshimura

Shuhei Miyazawa

Naoyuki Shimomura

Seiichi Kobayashi

Tetsuya Kawahara

Richard S Clark

Koukichi Harada

Kazuo Okano

Roch Boivin

Takashi Inoue

Yimin Jiang

Xiang-Yi Li

Takashi Mori

Toru Horie

Jesse Chow

Charles-André Lemelin

Kenichi Kusube

Hironori Ikuta

Kozo Akasaka

Youji Yamagishi

Tetsu Kawano

Ray Wood

Minghuang Zhang

John Wang

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

The present invention provides compositions comprising compounds having formula (I): 

The present invention provides compounds having formula (I): 

The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.

Methods of reducing the severity of mucositis

Naphthalene derivatives of the formula: ##STR1## wherein R.sup.1, represents a hydrogen atom, a lower alkyl group or an acyl group; R.sup.2 independently represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogen atom, a cycloalkyl group, a cycloalkylalkyl group, a hydroxyl group, an aryl group which may be substituted, an arylalkyl group whose aryl group may be substituted, a heteroaryl group, or a heteroaryllakyl group; R.sup.3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, an aryl group which may have a substituent, an arylalkyl group whose aryl group may be substituted, an arylalkenyl group whose aryl group may be substituted, a cycloalkyl group, an alkoxyalkyl group, a heteroaryl group, a heteroarylalkyl group, a carboxyl group, a carboxyalkyl group, an aminoalkyl group, or a cyano group; R.sup.6 is C.sub.1-6 alkyl; and m is 0 or an integer of from 1 to 2 useful in treating autoimmune diseases are disclosed.

Naphthalene derivative

A naphthalene derivative having the formula is new and useful for medicine. ##STR1## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or an acyl group;

Compounds of the formula: ##STR1## where R.sup.1 is a hydrogen atom or a lower alkyl group;

Naphthalene derivatives

The present invention relates to a naphthalene derivative. More particularly, it relates to a naphthalene derivative exhibiting an excellent activity as a drug.

A naphthalene derivative having the formula is new and useful for medicine. ##STR1## [wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or an acyl group;

3-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-2-pyrrolidone and N-substituted derivatives thereof are described. The substituent includes alkyl, alkoxy, alkynyl phenyl-alkylene, hydroxy-alkylene and amino-alkylene. They are effective as an anti-inflammatory, analgesic and antithermic agent, and they have a low toxicity.

3-(3,5-di-tert-butyl-4-hydroxy benzylidene)-2-pyrrolidone and

Growing community of inventors

Belmont, MA, United States of America

Hiroshi Shirota